

EQA round: RF2/23 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 29.9.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			

Set 1

(231) Rheumat. fac. (scr)	[kU/L]	169										154	122	79	
Sample A1		8,52	4,5	53	169		CVP	8,52	0,9	asym.	0	20	169	151	89
(1) Abbott		14,7	7,5	51	38	6							38		
(12) Beckman Coulter		20	0	0	5	1							5		
(58) Beckman Coulter (AU)		6,73	3,5	52	26	1							26		
(60) Roche		9,26	1,3	15	49	5							49		
(149) Siemens (Dade, BN, Dimension)		9,45	1,6	17	10	0							10		
(162) Siemens (Atellica)		5,21	3	58	13	1							13		
(177) Mindray		6,05	1,7	28	5	0							5		
(179) Siemens		4,75	1,9	39	8	1							8		
Other					15	2							15		
1x 70, 3x 91, 3x 115, 2x 116, 2x 148, 3x 178, 1x 999															

Sample B1		402	46	11	169								154	125	81
(1) Abbott		411	39	9,6	38	4	CVPG	411	17	33%	275	547	38		
(12) Beckman Coulter		496	63	13	5	1	CVPG	496	63	33%	332	660	5		
(58) Beckman Coulter (AU)		337	130	39	26	1	CVPG	337	64	33%	225	449	26		
(60) Roche		396	18	4,6	49	4	CVPG	396	6,7	33%	265	527	49		
(149) Siemens (Dade, BN, Dimension)		504	67	13	10	0	CVPG	504	52	33%	337	671	10		
(162) Siemens (Atellica)		384	14	3,6	13	1	CVPG	384	9,9	33%	257	511	13		
(177) Mindray		350	9	2,6	5	0	CVPG	350	26	33%	234	466	5		
(179) Siemens		416	72	17	8	1	CVPG	416	70	33%	278	554	8		
Other					15	3							0		
1x 70, 3x 91, 3x 115, 2x 116, 2x 148, 3x 178, 1x 999															

Set 2

(237) anti-streptolysin O (ASLO)	[kU/L]	165										146	146	100	
Sample A2		132	22	16	165								146	146	100
(1) Abbott		104	4,3	4,1	43	0	CVPG	104	1,6	20%	83,2	125	43		
(58) Beckman Coulter (AU)		139	7	5	30	0	CVPG	139	3,1	20%	111	167	30		
(60) Roche		144	9,6	6,7	45	0	CVPG	144	3,5	20%	115	173	45		
(149) Siemens (Dade, BN, Dimension)		139	7,4	5,3	8	0	CVPG	139	5,6	20%	111	167	8		
(162) Siemens (Atellica)		150	5,8	3,8	13	0	CVPG	150	3,9	20%	120	180	13		
(179) Siemens		155	6,7	4,3	7	0	CVPG	155	6,5	20%	124	186	7		
Other					19	0							0		
4x 12, 3x 91, 3x 115, 1x 116, 4x 177, 3x 178, 1x 999															

Sample B2		310	64	21	165								146	146	100
(1) Abbott		226	7,4	3,3	43	0	CVPG	226	2,8	20%	180	272	43		
(58) Beckman Coulter (AU)		319	14	4,3	30	0	CVPG	319	6,1	20%	255	383	30		
(60) Roche		354	21	6	45	0	CVPG	354	7,7	20%	283	425	45		
(149) Siemens (Dade, BN, Dimension)		346	13	3,6	8	0	CVPG	346	9,6	20%	276	416	8		
(162) Siemens (Atellica)		370	13	3,4	13	0	CVPG	370	8,6	20%	296	444	13		
(179) Siemens		358	30	8,3	7	0	CVPG	358	29	20%	286	430	7		
Other					19	0							0		
4x 12, 3x 91, 3x 115, 1x 116, 4x 177, 3x 178, 1x 999															